December 8, 2010

China Strategy

2011 Outlook: A Year of Re-rating

Several bullish themes for Chinese equities in 2011:

- 1) Cheap valuation, humble relative performance in 2010, and mild consensus outlook.
- Solid earnings growth outlook supported by expansive fiscal policies. Upside risk in large-caps.
- Contained inflation risk with stable monetary policies and moderate tightening.
- Strong currency, still ample global liquidity environment, good risk appetite.

Policy tone for 2011 – still pro-growth yet tackling inflation risk: The just concluded Politburo Working Meeting set the tone for 2011 fiscal policies as "appropriately accommodative" (same as 2010); monetary policies shifted to "stable and healthy" (from "appropriately accommodative" in 2010). This implies a balance between remaining pro-growth and curbing inflation risk.

We think mild inflation should favor stocks in 2011:

This is contrary to the Street view, which we find overly concerned about inflation. Our economist, Qing Wang, forecasts inflation to peak by mid-2010 with a full-year reading at 4.5%. In this vision, stocks should rise with inflation stabilizing and peaking in 2011.

We favor high beta, deep value and cyclical plays: Our favored industries are banks, property, insurance, steel, cement and energy. We underweight consumer stocks including durables, staples, auto and tech.

Loan quota is the key domestic risk for 2011: An overly tight new loan quota would be a drag on economic growth and squeeze bank asset quality. A too-loose loan quota could fuel greater inflation and trigger aggressive tightening.

G3 growth is the key external risk: Surprisingly higher than expected growth in the G3 economies could drive oil, commodities and food prices even higher, followed by global inflation spillover. China would be forced into more aggressive tightening in that case.

MORGAN STANLEY RESEARCH ASIA/PACIFIC

Morgan Stanley Asia Limited+

Jerry Lou

Jerry.Lou@morganstanley.com +852 2848 6511

Allen Gui

Allen.Gui@morganstanley.com

James Cao

James.Cao@morganstanley.com

Corey Ng, CFA

Corey.Ng@morganstanley.com

Year-End 2011 Index Targets

		2011Y	E index	target	Up-/Down-side				
Index	Current	Base	Bull	Bear	Base	Bull	Bear		
MSCI China	67.6	94.5	111.5	73.2	39.8%	65%	8%		
HSCEI	12,922	17,682	20,541	13,965	36.8%	59%	8%		

Source: Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

We Are Optimistic on the 2011 Outlook for Chinese Equities

Introducing Our Year-End 2011 Index Targets

We see several positive themes: Mild inflation, normalized liquidity, modest tightening, good growth, strong currency, cheap valuation, humble relative performance in 2010, and mild consensus outlook.

- We set our new year-end 2011 index targets for MSCI China at 94.5 (up 15.7% from 81.7 for year-end 2010) and for HSCEI at 17,682 (up 14.8% from 15,399 for year-end 2010). These targets imply 40% and 37% upside potential, respectively.
- We project YoY earnings growth of 14.9% for MSCI China and 16.4% for HSCEI in 2011.
- We also expect P/E multiple expansion of 20%, to 15.7x on average from current market levels of 13.1x.

We favor high-beta, cheaply valued and deep cyclical industries: These include banks, property, insurance, steel, cement and energy. We underweight all consumer sectors including durables, staples, auto and tech because we are not comfortable with their high valuation and high earnings expectations.

Loan quota is the key domestic risk and G3 growth is the key external risk: We are using our economist's forecast of Rmb 7 trillion new loans in 2011. If the actual quota turns out to be much less than this, we expect that stocks would fall due to over-tightening. If economies in the developed world surprise on the upside and recover quickly in 2011, oil and food prices would rise globally, forcing China to tighten aggressively. In that scenario, stocks would fall.


Liquidity, Inflation and Policies: Not a Vicious Spiral

Liquidity, inflation and policies interact with each other, but we do not envision a vicious spiral that would derail growth, as China's money supply already decelerated in 2H2010.

Indeed, our Greater China economist, Qing Wang, forecasts a new loan quota of Rmb 7 trillion and 4.5% inflation in 2010, with CPI peaking by the middle of the year. This is a very mild inflation picture for 2011, with good growth.

We, the strategy team, also see the possibility that CPI could peak even sooner in 1Q2011. Our monetary leading indicator (constructed by M1 and M2 information) shows clear downward trend pressure on CPI in the coming months and for the full year 2011 – if we assume Rmb 7 trillion new loans to be allocated across the 12 months in 2011 in the same proportion as they have been in 2010.

Exhibit 1
Monetary Leading Indicator Implies Downward
Trend of CPI in 2011: Assuming 7 Trillion New Loans



Source: CEIC, Morgan Stanley Research

Policy makers' change in tone has also confirmed this view: At the regular Working Meeting of the Politburo that just concluded, the tone for 2011 fiscal policies was "appropriately accommodative" (same as 2010); monetary policies shifted to "stable and healthy" (from appropriately accommodative in 2010). This implies a balance between remaining pro-growth and tackling inflation risk.

Finally, Rmb7 trillion in new loans is a very loose level of liquidity to fuel growth. Indeed, it represents 16% of GDP in 2011, which is still well above the 13% "normal" new loans to GDP ratio before the financial crisis (2005~2007 average). Clearly, this would not derail growth.

In conclusion, we can build a bull case on our economist's inflation and liquidity view in 2011, as CPI peaking by 2011 will be good news for equities. If CPI actually peaks earlier than that, as suggested by our monetary leading indicator, then it could trigger market re-rating in the next few months.

Growth Expectations: Moderate, with Upside Risk


In the past 10 years, MSCI China's EPS growth has averaged 15.5% YoY, compared to current consensus forecast of 14.9% for 2011. We think there are upside risks in consensus earnings forecasts, especially in the large-cap groups such as banks and energy.

MORGAN STANLEY RESEARCH

December 8, 2010 China Strategy

Exhibit 2

MSCI China Earnings Estimate Revision Trend



Source: IBES, MSCI, Morgan Stanley Research

The market is pricing in little expansion in banks' net interest margin next year. However, we think this implies earnings upside for the industry, since we envisage interest rate normalization next year. Assuming average NIM rebounds to the 2007 level of 3% (our analysts now expect just 2.4%), the big five banks would net about Rmb125bn extra after-tax profit on top of the current estimate of 620 bn. That would dramatically lift their 2011 earnings growth from 18.7% to 42.7% on average.

For the energy industry, every US\$1 rise in oil prices would also add roughly 1% to the oil companies' combined earnings growth in 2011 – currently the oil price assumed by our analysts is US\$95.

For other smaller industries such as capital goods, steel and cement, we believe the solid execution and delivery of social housing projects in 2011 (see Qing Wang's report 2011: A Year of Reflation, Nov 22, 2010) could also prompt increased earnings estimates.

Valuation Attractive, Currency Should Support

MSCI China is trading at P/E multiples of 14.0x for 2010e and 12.2x for 2011e, based on consensus estimates. This is attractive compared to the historical average in the past decade of 13.8x FY1 PE. A 2011e P/E of 12.2x is also very close to half a standard deviation line below the long-term average – a historically strong support level. Also considering the humble performance of MSCI China in 2010 (up 4.3% year-to-date), we think that overall, the market's downside risk in 2011 should be very limited.

Exhibit 3

MSCI China Valuation Trend



Source: IBES, Morgan Stanley Research

The A-share market is trading at a discount to its H-share counterpart – which is very rare (only the third time in 10 years). This also suggests strong performance over the next 12 months in both the A-share and H-share markets.

A/H Premium vs. Market NTM Return



Source: Factset, Morgan Stanley Research

Our economist also believes that Rmb strengthening will continue in 2011 at an annualized rate of 6.5% (see Qing Wang's report 2011: A Year of Reflation, November 22, 2010). Clearly this is not what the market is now pricing in (RMB 12-month NDF premium to spot rate is only 2.4% now). This implies strong re-rating potential in market valuation, given the close correlation between Rmb appreciation expectations and Chinese market valuation.

MORGAN STANLEY RESEARCH

December 8, 2010 China Strategy

Exhibit 5 Rmb NDF Premium to Spot vs. Market Valuation




Source: Bloomberg, Morgan Stanley Research

From a relative performance perspective, we think it is also quite unlikely that MSCI China would underperform the regional market for a third consecutive year – unless fundamentals were exceptionally weak. Between 1993 and 1995, China underperformed AXJ for three consecutive years because the "Asian tigers" were booming amid an asset bubble, while China's domestic economy suffered a hard landing after severe inflation and the bursting of an asset bubble in Hainan Island property.

Today's relative fundamental outlook is exactly the opposite: China's economic strength and corporate fundamentals are probably the strongest in the region, yet it has underperformed the region continuously for two years. We think a third year of such mispricing is highly unlikely against this fundamental backdrop.

Exhibit 6
MSCI China Relative Performance to MSCI AC AXJ



Source: MSCI, Morgan Stanley Research

Index Targets: 37% and 40% Upside

We set our new index targets for MSCI China and HSCEI at 94.5 and 17682, implying 40% and 37% upside respectively, mainly driven by 2011 earnings growth of 14.9% and 16.4% from 2010, and PE multiple expansion of 20% from current market levels.

Assuming real GDP growth of 9% in 2011, our model indicates a forward earnings multiple of 14.58x, based on the historical relationship between growth and valuation. Assuming 6.5% Rmb appreciation in 2011, our model indicates 19x, based on the historical relationship between Rmb appreciation and valuation. We believe the achievable market forward PE should settle between these two. We thus use the median, 16.79x, as the target multiple for 2011.


Exhibit 7
Index Targets for Year-End 2011

		<u>2011Y</u>	2011YE index target			Up-/Down-side				
Index	Current	Base	Bull	Bear	Base	Bull	Bear			
MSCI China	67.6	94.5	111.5	73.2	39.8%	65%	8%			
HSCEI	12,922	17,682	20,541	13,965	36.8%	59%	8%			

Source: Morgan Stanley Research estimates

Exhibit 8

MSCI China Index Target Scenarios




Source: Morgan Stanley Research

MORGAN STANLEY RESEARCH

December 8, 2010 China Strategy

Exhibit 9 HSCEI Index Target Scenarios




Source: Morgan Stanley Research

Asset Allocation Strategy: We Are Contrarians

Reviewing our 2010 asset allocation, we employed a low-beta strategy in 1H2010 and turned to a high-beta strategy since mid-2010.

Exhibit 10

China Model Portfolio Performance



MP performance is measured by weighted average return of its constituents; initial MP price is indexed at 100 on 11/30/2009; portfolio is rebalanced immediately after changes; assuming no currency hedging, no trading costs, and no dividends. Note: past performance is no guarantee of future results. Source: Factset, Morgan Stanley Research


We are carrying forward our high-beta strategy into 2011:

We have a great focus on value, as we believe deep value and highly cyclical sectors can beat the market significantly throughout the process of re-rating.

Our favored industries are banks, properties, insurance, steel, cement and energy. We underweight transportation, auto, durables, staples, and technology.

Exhibit 1

China Model Portfolio: Industry Over-/Under-weight



Source: Morgan Stanley Research

Exhibit 12
China Model Portfolio

Name	MS Rating	MSCI China Weight	Portfolio Weight	Overweight/ Underweight	Price Current	2010E PE	2010E EPS Gth.		2010E Div. Yields	Market Cap.	3-Mth Perform.	12-Mth Perform
Davids.		04.70	(%)	(bps)	(local curr)	(x)		(x)		(US\$m)		
Banks Bank of China Limited	Equal-Weight	21.73	28.0	627	4.19	9.5 e	18% e	1.0 -	4.4% e	137,044	7.40/	(4.40(
		4.83	8.0	317				1.6 e			7.4%	(1.1%)
Bank of Communications	Overweight	1.01	4.0	299	8.17	9.6 e	19% e	1.8 e	3.8% e	59,226	(3.5%)	(6.7%)
China Construction Bank Corp.	++	6.26	8.0	174	7.06	10.8 e	23% e	2.3 e	3.8% e	204,397	10.6%	2.2%
Industrial and Commercial Bank of China	Overweight	6.70	8.0	130	5.97	10.7 e	24% e	2.2 e	3.8% e	256,941	4.2%	(8.4%)
Capital Goods		3.18	2.0	-118								
ZPMC B-Share	NA	0.00	2.0	200	0.62	29.2 e	26% e	1.0 e	NA	527	13.5%	(29.0%)
Consumer Durables & Apparel	_	2.73	1.0	-173								
China Dongxiang Group Co. Ltd	Overweight	0.18	1.0	82	3.45	10.3 e	9% e	2.0 e	5.8% e	2,519	(17.9%)	(40.8%)
Energy		17.23	18.0	77								
CNOOC	Overweight	6.06	9.0	294	18.36	13.6 e	74% e	3.4 e	2.6% e	104,807	35.6%	52.7%
PetroChina	Equal-Weight	3.91	4.5	59	10.10	13.2 e	16% e	1.7 e	3.4% e	238,183	16.2%	2.7%
China Petroleum & Chemical Corp.	Equal-Weight	2.13	2.0	-13	7.22	8.6 e	1% e	1.3 e	2.9% e	80,659	13.9%	10.6%
China Shenhua Energy	Overweight	1.98	2.5	52	31.30	14.3 e	17% e	2.7 e	2.4% e	80,217	3.6%	(18.8%)
Food Beverage & Tobacco		4.05	3.0	-105								
China Foods Limited	Underweight	0.00	2.0	200	5.27	29.6 e	13% e	2.5 e	1.0% e	1,895	(7.7%)	(27.6%)
Yantai Changyu B-share	Overweight	0.00	1.0	100	87.37	27.7 e	26% e	10.3 e	1.6% e	7,218	(0.9%)	33.4%
Insurance		8.46	11.0	254								
China Life Insurance	Overweight	4.62	8.0	338	33.30	23.0 e	11% e	3.6 e	1.3% e	121,276	8.6%	(18.8%)
Ping An Insurance Company	Overweight	2.92	3.0	8	91.50	33.9 e	22% e	5.1 e	0.9% e	86,597	30.2%	23.7%
Materials		5.88	8.0	212								
China National Building Material Company		0.49	2.0	151	17.90	11.6 e	38% e	2.2 e	0.4% e	5,723	14.7%	3.8%
China Shanshui Cement Group	Overweight	0.20	2.0	180	6.43	14.7 e	49% e	2.6 e	1.7% e	2,333	31.2%	6.6%
Maanshan Iron & Steel	Overweight	0.14	2.0	186	4.35	22.1 e	230% e	1.0 e	1.1% e	4,316	(9.9%)	(19.4%)
Angang Steel Company Limited	Underweight	0.23	2.0	177	11.54	23.0 e	313% e	1.3 e	2.1% e	10,758	(11.4%)	(30.6%)
Real Estate		5.81	9.0	319								
Vanke B-Share	NA	0.25	2.0	175	10.64	14.3 e	33% e	2.3 e	NA	1,804	9.2%	5.4%
China Overseas Land & Inv.	Equal-Weight	1.16	2.0	84	15.26	15.9 e	20% e	2.6 e	1.6% e	16,071	(12.3%)	(17.2%)
China Resources Land	Equal-Weight	0.23	4.0	377	14.00	18.3 e	19% e	1.8 e	1.7% e	9,087	(12.6%)	(30.0%)
KWG Property Holding Limited	Overweight	0.16	1.0	84	6.40	13.2 e	62% e	1.3 e	1.9% e	2,139	5.4%	(5.0%)
Retailing	O vo. worg. k	1.96	1.0	-96	0.10	10.2 0	02700	7.0 0	1.0700	2,100	0.470	(0.070)
Parkson Retail Group Limited	Equal-Weight	0.31	1.0	69	12.68	31.5 e	14% e	7.3 e	0.0 e	4,586.5	(7.6%)	(6.2%)
Telecommunication Services	Lquai-weight	11.13	12.0	87	12.00	31.3 6	1470 6	7.5 6	0.0 6	4,300.3	(7.0%)	(0.2%)
China Mobile Limited	Equal-Weight	8.80	6.0	-280	78.95	11.7 e	2% e	2.4 e	3.7% e	208.424	(3.7%)	8.1%
China Telecom	Equal-Weight	1.02	3.0	198	3.96	16.2 e	13% e	1.2 e	2.1% e	41,296	(2.7%)	14.5%
China Unicom		1.15	3.0	185	10.74	81.1 e	68% e	1.2 e	1.7% e		(7.3%)	6.3%
Transportation	Overweight	3.21	1.0	-221	10.74	61.1 e	00% E	1.1 e	1.7% E	33,178	(1.376)	0.370
Air China Limited	Equal-Weight	0.41	0.5	9	10.08	8.3 e	164% e	3.0 e	2.4% e	15.553	9.0%	59.7%
China Southern Airlines	Equal-Weight	0.41	0.5	NA NA	5.32	o.s e NM	164% e NM	1.8 e	2.4% €	1,317.2	7.2	-2.5
Utilities	Equal-vveignt	2.00	2.0	0	5.52	INIVI	INIVI	1.0 €		1,317.2	1.2	-2.5
China Everbright International Limited	Overweight	0.00	2.0	200	4.32	31.6 e	24% e	3.1 e	0.3% e	2.062	21.7%	11.6%
Media & Internet	Overweight	3.29	4.0	71	4.32	31.0 6	24 % E	3.1 6	0.5 % E	2,002	21.770	11.076
Netease.com	Overweight	0.00	1.0	100	39.77	16.2 e	13% e	3.6 e	0.0% e	5,192	5.9%	5.4%
Sohu.com Inc	Overweight	0.00	1.0	100	39.77 76.71	20.6 e	13% e 1% e	3.5 e 3.7 e	0.0% e 0.0% e	2,937	5.9% 52.4%	5.4% 44.2%
VisionChina Media	Overweight	0.00	1.0	100	3.65	20.6 e NM	1% e NM	3.7 e 1.3 e	0.0% e 0.0% e	2,937	(1.2%)	(66.6%)
Giant Interactive					7.09	13.8 e	7% e	1.7 e	0.0% e 2.6% e	1,655		
TOTAL	Overweight	0.00	1.0 100.0	100	7.09	13.8 e	7% e	1.7 e	∠.0% €	1,655	15.7%	0.0%
MSCI China						17.6					8.2%	1.2%
MOOI CHIIII)									0.2%	1.2%

Prices as of December 7, 2010. Past performance is no guarantee of future results. Results shown do not include transaction costs. E = Morgan Stanley estimates (except for ZPMC B-shares and Vanke B, for which we use consensus estimates as a Morgan Stanley estimate no longer provides coverage). ++Estimates, rating, and/or price target for this company have been removed from consideration in this report because, under applicable law and/or Morgan Stanley policy, Morgan Stanley may be precluded from issuing such information with respect to this company at this time. Source: IBES, Morgan Stanley Research

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 1992/06298Z, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 2000/08434H, regulated by the Monetary Authority of Singapore, which accepts the responsibility for its contents), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Apalyses Contribution: Research Management), New York, NY, 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies

As of October 29, 2010, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Angang Steel Company Limited, Bank of China Limited, China Life Insurance, China National Building Material Company, China Overseas Land & Inv., China Petroleum & Chemical Corp., China Resources Land, China Shanshui Cement Group, China Telecom, China Vanke Co., Ltd., Netease.com, PetroChina, Ping An Insurance Company, Sohu.com Inc, Yantai Changyu Pioneer Wine Company Ltd.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of China Mobile Limited, China National Building Material Company, KWG Property Holding Limited, Ping An Insurance Company.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from China National Building Material Company, Industrial and Commercial Bank of China, KWG Property Holding Limited, PetroChina.

In the next 3 months, Morgan Stanley has received compensation for investment banking services from Air China Limited, Angang Steel Company Limited, Bank of China Limited, China Construction Bank Corp., China Foods Limited, China Life Insurance, China Mobile Limited, PetroChina, Ping An Insurance Company.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Air China Limited, PetroChina, Ping An Insurance Company.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Air China Limited, Bank of China Limited, Bank of Communications, China Construction Bank Corp., China Everbright International Limited, China Life

An employee, director or consultant of Morgan Stanley (not a research analyst or a member of a research analyst's household) is a director of China Dongxiang Group Co. Ltd, China Shanshui Cement Group.

Morgan Stanley & Co. Incorporated makes a market in the securities of Giant Interactive, Netease.com, Sohu.com Inc, VisionChina Media.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of November 30, 2010)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage Universe		Investment Banking Clients (IBC)			
_	% of		% of % o		% of Rating	
Stock Rating Category	Count	Total	Count	Total IBC	Category	
Overweight/Buy	1121	40%	417	44%	37%	
Equal-weight/Hold	1175	42%	410	43%	35%	
Not-Rated/Hold	119	4%	26	3%	22%	
Underweight/Sell	392	14%	105	11%	27%	
Total	2,807		958			

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Not-Rated (NR) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country MSCI Index on a risk-adjusted basis, over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant

broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of China Construction Bank Corp., China Mobile Limited, China Petroleum & Chemical Corp., CNOOC, KWG Property Holding Limited, Parkson Retail Group Limited.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

The fixed income research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments

MORGAN STANLEY RESEARCH

December 8, 2010 China Strategy

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. Information on any securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK")'s Hang Seng China Enterprise Index; or any securities/instruments issued by a company that is 30% or more directly- or indirectly-owned by the government of or a company incorporated in the PRC and traded on an exchange in Hong Kong or Macau, namely SEHK's Red Chip shares, including the component company of the SEHK's China-affiliated Corp Index is distributed only to Taiwan Securities Investment Trust Enterprises ("SITE"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Stanley Asia Limited.

Morgan Stanley Research is disseminated in Japan by Morgan Stanley MUFG Securities Co., Ltd.; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 1992062982) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore, which accepts responsibility for its contents; in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited, in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for, the contents of Morgan Stanley Research in Canada; in Germany by Morgan Stanley Bank AG, Frankfurt am Main and Morgan Stanley Private Wealth Management Limited, Niederlassung Deutschland, regulated by Bundesanstalt fuer Finanzidienstleistungsaufsicht (BaFin); in Spain by Morgan Stanley, S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in accordance with the rules of conduct applicable to financial research as established under Spanish regulations; in the United States by Morgan Stanley & Co. Incorporated, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized and regulated by the Financial S a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

MORGAN STANLEY RESEARCH

The Americas 1585 Broadway New York, NY 10036-8293 United States Tel: +1 (1) 212 761 4000

Europe 20 Bank Street, Canary Wharf London E14 4AD United Kingdom Tel: +44 (0) 20 7 425 8000 Japan 4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000 Asia/Pacific

1 Austin Road West
Kowloon
Hong Kong
Tel: +852 2848 5200